The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing

Article Oncology

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia

Franco Locatelli et al.

Summary: The results of this study demonstrate that Blinatumomab is more effective than high-risk third course consolidation chemotherapy (HC3) in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL), independent of MRD status.

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Article Hematology

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Nicholas J. Short et al.

Summary: This study evaluated the clinical impact of a highly sensitive next-generation sequencing (NGS) MRD assay in acute lymphoblastic leukemia (ALL) patients. The study found that NGS detection could identify patients with a significant risk of relapse, even if they were considered MRD negative by multiparameter flow cytometry (MFC). Early assessment of MRD using NGS provides important prognostic information for predicting relapse risk and long-term survival in ALL patients.

BLOOD ADVANCES (2022)

Add to Collection

Review Oncology

Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside

Xinyue Deng et al.

Summary: Minimal residual disease (MRD) is the strongest predictor of prognosis and a crucial factor in treatment decisions for hematological malignancies. Advances in new strategies have resulted in deeper responses in patients, making it challenging for the widely used gold-standard techniques of MRD monitoring. High-throughput technologies, such as next-generation sequencing (NGS)-based clonality assays, are recommended as disease-monitoring modalities due to their sensitivity and ability to provide sufficient information.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Meeting Abstract Hematology

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Emily C. Liang et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Mark R. Litzow et al.

BLOOD (2022)

Add to Collection

Article Oncology

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario

Anne Tierens et al.

Summary: Measurable residual disease (MRD) testing is crucial in adult B-cell acute lymphoblastic leukemia (B-ALL) for prognostic purposes, yet there is a lack of uniform guidelines and consensus in Canada, leading to significant variability in testing approaches. Experts recommend centralized MRD testing and different testing strategies for Ph-negative and Ph-positive patients.

CURRENT ONCOLOGY (2021)

Add to Collection

Review Hematology